http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2817778-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3b53e07b4427a2686e8f443721d06500 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H30-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H50-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H50-50 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16H50-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G06F19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16H30-40 |
| filingDate | 2009-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-04-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9c11e45634dcc77f97efd50140f84956 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_28a60cc34c5961f6c495b8c54d827f48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bdbbf210754405f3e76862d7893dcd56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_afe4217bb4276e623d4333891c4ab446 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_079f38f9e17bf42507883e5353affe47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eeed6bef279e08d5bed265f2ea6b8aad http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f4a3c3bcddb18ed67151c367ac6483db http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_72985d847b177d967ffd656ce65ed5a9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_28111c9fedbbf144ac6722996c8bbe36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_42603123e1fff2964c2f55b311964445 |
| publicationDate | 2021-04-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2817778-T3 |
| titleOfInvention | Systems and methods for treating, diagnosing, and predicting the onset of a medical condition |
| abstract | Apparatus for evaluating whether a patient is likely to have a favorable pathological stage of prostate cancer, the apparatus comprises: (a) a fluorescence imaging device configured to record at least one sample image of a tissue sample from a patient, the tissue sample treated with a plurality of fluorochrome-labeled antibodies, wherein the antibodies are selected to bind with at least AR and Ki67; (b) a database configured to store patient data that includes clinical characteristic data values for the patient comprising a value indicative of the biopsy Gleason score (bGS) and the biopsy Gleason grade ( bGG) of the patient and a value indicative of the level of prostate specific antigen (PSA) in the patient's blood; and (c) a processor configured to: (i) evaluate the at least one sample image recorded by the imaging device and generate: one or more molecular characteristic values indicative of a combined AR dynamic range where the values of Measured bGG are <= 3, and a total Ki67 where the measured bGG value is> = 4, and a plurality of morphometric measurements, including: (i) a relationship between the area of epithelial nuclei outside the gland units and the area of epithelial nuclei within the gland units; and (ii) an area of epithelial nuclei distributed away from the gland units; (ii) combine the molecular characteristic values, morphometric measurements, and clinical characteristic data values in the database; (iii) evaluate patient data with a predictive model configured to generate a value based on the evaluated characteristics; and (iv) assign the patient to a low risk category for cancer development when the exit value is below a predetermined threshold and assign the patient to a high risk category when the exit value is above the predetermined threshold . |
| priorityDate | 2008-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 163.